145 related articles for article (PubMed ID: 31957240)
21. Identifying miRNA-mediated signaling subpathways by integrating paired miRNA/mRNA expression data with pathway topology.
Vrahatis AG; Dimitrakopoulos GN; Tsakalidis AK; Bezerianos A
Annu Int Conf IEEE Eng Med Biol Soc; 2015; 2015():3997-4000. PubMed ID: 26737170
[TBL] [Abstract][Full Text] [Related]
22. Topologically inferring active miRNA-mediated subpathways toward precise cancer classification by directed random walk.
Ning Z; Feng C; Song C; Liu W; Shang D; Li M; Wang Q; Zhao J; Liu Y; Chen J; Yu X; Zhang J; Li C
Mol Oncol; 2019 Oct; 13(10):2211-2226. PubMed ID: 31408573
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive analysis of microglia gene and subpathway signatures for glioma prognosis and drug screening: linking microglia to glioma.
Zhang C; Zhao J; Mi W; Zhang Y; Zhong X; Tan G; Li F; Li X; Xu Y; Zhang Y
J Transl Med; 2022 Jun; 20(1):277. PubMed ID: 35729639
[TBL] [Abstract][Full Text] [Related]
24. Identification of 17 mRNAs and a miRNA as an integrated prognostic signature for lung squamous cell carcinoma.
Zhang J; Bing Z; Yan P; Tian J; Shi X; Wang Y; Yang K
J Gene Med; 2019 Aug; 21(8):e3105. PubMed ID: 31215090
[TBL] [Abstract][Full Text] [Related]
25. MiRNA-Mediated Subpathway Identification and Network Module Analysis to Reveal Prognostic Markers in Human Pancreatic Cancer.
Liu Y; Cui Y; Bai X; Feng C; Li M; Han X; Ai B; Zhang J; Li X; Han J; Zhu J; Jiang Y; Pan Q; Wang F; Xu M; Li C; Wang Q
Front Genet; 2020; 11():606940. PubMed ID: 33362865
[TBL] [Abstract][Full Text] [Related]
26. miRNA and mRNA cancer signatures determined by analysis of expression levels in large cohorts of patients.
Zadran S; Remacle F; Levine RD
Proc Natl Acad Sci U S A; 2013 Nov; 110(47):19160-5. PubMed ID: 24101511
[TBL] [Abstract][Full Text] [Related]
27. Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets.
Kuznetsov VA; Tang Z; Ivshina AV
BMC Genomics; 2017 Oct; 18(Suppl 6):692. PubMed ID: 28984201
[TBL] [Abstract][Full Text] [Related]
28. Recurrence-Associated Multi-RNA Signature to Predict Disease-Free Survival for Ovarian Cancer Patients.
Zhang Y; Ye Q; He J; Chen P; Wan J; Li J; Yang Y; Li X
Biomed Res Int; 2020; 2020():1618527. PubMed ID: 32149080
[TBL] [Abstract][Full Text] [Related]
29. A Novel Cluster-Based Computational Method to Identify miRNA Regulatory Modules.
Luo J; Pan C; Xiang G; Yin Y
IEEE/ACM Trans Comput Biol Bioinform; 2019; 16(2):681-687. PubMed ID: 29993835
[TBL] [Abstract][Full Text] [Related]
30. An integrated model of clinical information and gene expression for prediction of survival in ovarian cancer patients.
Yang R; Xiong J; Deng D; Wang Y; Liu H; Jiang G; Peng Y; Peng X; Zeng X
Transl Res; 2016 Jun; 172():84-95.e11. PubMed ID: 27059002
[TBL] [Abstract][Full Text] [Related]
31. Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells.
Ho SM; Lau KM; Mok SC; Syed V
Oncogene; 2003 Jul; 22(27):4243-56. PubMed ID: 12833147
[TBL] [Abstract][Full Text] [Related]
32. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression.
Liang H; Yu T; Han Y; Jiang H; Wang C; You T; Zhao X; Shan H; Yang R; Yang L; Shan H; Gu Y
Mol Cancer; 2018 Aug; 17(1):119. PubMed ID: 30098599
[TBL] [Abstract][Full Text] [Related]
33. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening.
Häusler SF; Keller A; Chandran PA; Ziegler K; Zipp K; Heuer S; Krockenberger M; Engel JB; Hönig A; Scheffler M; Dietl J; Wischhusen J
Br J Cancer; 2010 Aug; 103(5):693-700. PubMed ID: 20683447
[TBL] [Abstract][Full Text] [Related]
34. Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value.
Liu J; Tan Z; He J; Jin T; Han Y; Hu L; Song J; Huang S
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33043974
[TBL] [Abstract][Full Text] [Related]
35. LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms.
Braga EA; Fridman MV; Moscovtsev AA; Filippova EA; Dmitriev AA; Kushlinskii NE
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238475
[TBL] [Abstract][Full Text] [Related]
36. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
Fan CN; Ma L; Liu N
J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
[TBL] [Abstract][Full Text] [Related]
37. Integration of miRNA and mRNA Expression Data for Understanding Etiology of Gynecologic Cancers.
Paul S
Methods Mol Biol; 2019; 1912():323-338. PubMed ID: 30635900
[TBL] [Abstract][Full Text] [Related]
38. Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma.
Jayawardana K; Schramm SJ; Tembe V; Mueller S; Thompson JF; Scolyer RA; Mann GJ; Yang J
J Invest Dermatol; 2016 Jan; 136(1):245-254. PubMed ID: 26763444
[TBL] [Abstract][Full Text] [Related]
39. Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer.
Thériault BL; Pajovic S; Bernardini MQ; Shaw PA; Gallie BL
Int J Cancer; 2012 Apr; 130(8):1844-54. PubMed ID: 21618518
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas.
Qian Z; Li Y; Fan X; Zhang C; Wang Y; Jiang T; Liu X
J Neurooncol; 2018 Mar; 137(1):127-137. PubMed ID: 29204839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
